Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5
mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in
Japanese patients with both of hypertension and hypercholesterolemia, or with both angina
pectoris and hypercholesterolemia.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.